{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:13:54Z","timestamp":1760148834748,"version":"build-2065373602"},"reference-count":79,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>It is unclear to what extent systemic arterial blood pressure influences portal pressure. This relationship is clinically important as drugs, which are conventionally used for therapy of portal hypertension, may also influence systemic arterial blood pressure. This study investigated the potential correlation between mean arterial (MAP) and portal venous pressure (PVP) in rats with healthy livers. In a rat model with healthy livers, we investigated the effect of manipulation of MAP on PVP. Interventions consisted of 0.9% NaCl (group 1), 0.1 mg\/kg body weight (bw) Sildenafil (low dose), an inhibitor of phosphodiesterase-5 (group 2), and 1.0 mg\/kg bw Sildenafil (high dose, group 3) in 600 \u00b5L saline injected intravenously. Norepinephrine was used to increase MAP in animals with circulatory failure while PVP was monitored. Injection of the fluids induced a transient drop in MAP and PVP, probably due to a reversible cardiac decompensation. The drop in MAP and drop in PVP are significantly correlated. The time lag between change in MAP and change in PVP by 24 s in all groups suggests a cause-and-effect relationship. Ten minutes after the injection of the fluid, cardiac function was normalized. Thereafter, MAP gradually decreased. In the NaCl group, PVP decreases by 0.485% for a 1% drop of MAP, by 0.550% in the low-dose sildenafil group, and by 0.651% in the high-dose sildenafil group (p &lt; 0.05 for difference group two vs. group one, group three vs. group one, and group three vs. group two). These data suggest that Sildenafil has an inherent effect on portal pressure that exceeds the effect of MAP. Injection of norepinephrine led to a sudden increase in MAP followed by an increase in PVP after a time lag. These data show a close relationship between portal venous pressure and systemic arterial pressure in this animal model with healthy livers. A change in MAP is consequently followed by a change in PVP after a distinct time lag. This study, furthermore, suggests that Sildenafil influences portal pressure. Further studies should be performed in a model with cirrhotic livers, as these may be important in the evaluation of vasoactive drugs (e.g., PDE-5-inhibitors) for therapy of portal hypertension.<\/jats:p>","DOI":"10.3390\/ijms24129963","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T09:54:32Z","timestamp":1686304472000},"page":"9963","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Close Relationship between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver"],"prefix":"10.3390","volume":"24","author":[{"given":"Adhara","family":"Lazaro","sequence":"first","affiliation":[{"name":"Institute of Exercise and Occupational Medicine, Faculty of Medicine, Medical Center, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Stoll","sequence":"additional","affiliation":[{"name":"Narkose Suedbaden, 79110 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6219-3528","authenticated-orcid":false,"given":"Dominik","family":"von Elverfeldt","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Division of Medical Physics, Faculty of Medicine, Medical Center, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6884-0135","authenticated-orcid":false,"given":"Wolfgang","family":"Kreisel","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, Faculty of Medicine, Medical Center, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3291-884X","authenticated-orcid":false,"given":"Peter","family":"Deibert","sequence":"additional","affiliation":[{"name":"Institute of Exercise and Occupational Medicine, Faculty of Medicine, Medical Center, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cld.2019.07.007","article-title":"Portal Hypertension: Pathogenesis and Diagnosis","volume":"23","author":"Turco","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/egh.12.83","article-title":"Assessing portal hypertension in liver diseases","volume":"7","author":"Berzigotti","year":"2013","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(21)00175-8","article-title":"Pathophysiology of portal hypertension","volume":"21","author":"Bosch","year":"1992","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrgastro.2009.149","article-title":"The clinical use of HVPG measurements in chronic liver disease","volume":"6","author":"Bosch","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1097\/MCG.0b013e3181572357","article-title":"Vascular deterioration in cirrhosis: The big picture","volume":"41","author":"Bosch","year":"2007","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cld.2020.04.011","article-title":"Evaluation and Management of Esophageal and Gastric Varices in Patients with Cirrhosis","volume":"24","author":"Jakab","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.dld.2007.12.007","article-title":"Diagnosis and monitoring of portal hypertension","volume":"40","author":"Primignani","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014Renewing consensus in portal hypertension","volume":"76","author":"Bosch","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccc.2016.02.004","article-title":"The Circulatory System in Liver Disease","volume":"32","author":"Hollenberg","year":"2016","journal-title":"Crit. Care Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","article-title":"Functional aspects on the pathophysiology of portal hypertension in cirrhosis","volume":"57","author":"Bosch","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00535-016-1190-4","article-title":"Hepatic sinusoids in liver injury, inflammation, and fibrosis: New pathophysiological insights","volume":"51","author":"Greuter","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/hep.27343","article-title":"Molecular pathophysiology of portal hypertension","volume":"61","author":"Fernandez","year":"2015","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments","volume":"62","author":"Bosch","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000374099","article-title":"Pathophysiology and a Rational Basis of Therapy","volume":"33","author":"Bosch","year":"2015","journal-title":"Dig. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","article-title":"Pathophysiology of portal hypertension","volume":"18","author":"Iwakiri","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jhep.2014.05.047","article-title":"Vascular pathobiology in chronic liver disease and cirrhosis\u2014Current status and future directions","volume":"61","author":"Iwakiri","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-017-9827-9","article-title":"The portal hypertension syndrome: Etiology, classification, relevance, and animal models","volume":"12","author":"Bosch","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","article-title":"Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?","volume":"53","author":"Thabut","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/0140-6736(91)91384-7","article-title":"Hyperdynamic circulation in cirrhosis: A role for nitric oxide?","volume":"337","author":"Vallance","year":"1991","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/liv.13589","article-title":"The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis","volume":"38","author":"Bendtsen","year":"2018","journal-title":"Liver Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.3748\/wjg.v20.i10.2555","article-title":"Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis","volume":"20","author":"Bolognesi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/gut.2007.144584","article-title":"Mechanisms of extrahepatic vasodilation in portal hypertension","volume":"57","author":"Hennenberg","year":"2008","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","article-title":"The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule","volume":"43","author":"Iwakiri","year":"2006","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.tips.2015.05.001","article-title":"Nitric oxide in liver diseases","volume":"36","author":"Iwakiri","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","article-title":"Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kreisel, W., Lazaro, A., Trebicka, J., Perdekamp, M.G., Schmitt-Graeff, A., and Deibert, P. (2021). Cyclic GMP in Liver Cirrhosis\u2014Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910372"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJM198710013171403","article-title":"Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices","volume":"317","author":"Pascal","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0036-1597891","article-title":"The Design of Clinical Trials in Portal Hypertension","volume":"37","author":"Abraldes","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.jhepr.2019.12.001","article-title":"Beta-blockers in cirrhosis: Evidence-based indications and limitations","volume":"2","author":"Rodrigues","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12072-017-9833-y","article-title":"Pharmacologic prevention of variceal bleeding and rebleeding","volume":"12","author":"Baiges","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2036.2006.02735.x","article-title":"Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver\u2014Results of a pilot study","volume":"23","author":"Deibert","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.3748\/wjg.v24.i38.4356","article-title":"Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension","volume":"24","author":"Schaffner","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.dld.2014.10.018","article-title":"The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study","volume":"47","author":"Kreisel","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kreisel, W., Schaffner, D., Lazaro, A., Trebicka, J., Merfort, I., Schmitt-Graeff, A., and Deibert, P. (2020). Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176223"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.12703\/P6-95","article-title":"Future therapy of portal hypertension in liver cirrhosis\u2014A guess","volume":"6","author":"Sauerbruch","year":"2014","journal-title":"F1000Prime Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.13943.1","article-title":"Managing portal hypertension in patients with liver cirrhosis","volume":"7","author":"Sauerbruch","year":"2018","journal-title":"F1000Research"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cld.2013.12.003","article-title":"Pharmacologic management of portal hypertension","volume":"18","author":"Berzigotti","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-0039-1693115","article-title":"Vascular Targets for the Treatment of Portal Hypertension","volume":"39","author":"Brusilovskaya","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.30314","article-title":"Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension","volume":"69","author":"Abraldes","year":"2019","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.3748\/wjg.v21.i20.6117","article-title":"Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis","volume":"21","author":"Garbuzenko","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.3748\/wjg.v24.i33.3738","article-title":"Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives","volume":"24","author":"Garbuzenko","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.1840090603","article-title":"Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal-systemic shunting","volume":"9","author":"Kravetz","year":"1989","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/jhep.2001.23437","article-title":"Effects of blood volume restitution following a portal hypertensive\u2013related bleeding in anesthetized cirrhotic rats","volume":"33","year":"2001","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Halverscheid, L., Deibert, P., Schmidt, R., Blum, H.E., Dunkern, T., Pannen, B.H., and Kreisel, W. (2009). Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver. BMC Gastroenterol., 9.","DOI":"10.1186\/1471-230X-9-69"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd4623","article-title":"Strategies to increase nitric oxide signalling in cardiovascular disease","volume":"14","author":"Lundberg","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMsa063904","article-title":"Nitric Oxide and Cyclic GMP in Cell Signaling and Drug Development","volume":"355","author":"Murad","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM196610062751403","article-title":"Effect of Plasma-Volume Expansion on Portal Hypertension","volume":"275","author":"Boyer","year":"1966","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Van Limmen, J., Wyffels, P., Berrevoet, F., Vanlander, A., Coeman, L., Wouters, P., De Hert, S., and De Baerdemaeker, L. (2020). Effects of propofol and sevoflurane on hepatic blood flow: A randomized controlled trial. BMC Anesthesiol., 20.","DOI":"10.1186\/s12871-020-01150-3"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2013.09.016","article-title":"The changing role of beta-blocker therapy in patients with cirrhosis","volume":"60","author":"Ge","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.1840080103","article-title":"Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: A prospective, randomized study","volume":"8","author":"Bellati","year":"1988","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0168-8278(88)80515-4","article-title":"Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial","volume":"7","author":"Lebrec","year":"1988","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJM198112033052302","article-title":"Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A controlled study","volume":"305","author":"Lebrec","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/gut.26.4.421","article-title":"B1 selective adrenoreceptor blockade for the long term management of variceal bleeding. A prospective randomised trial to compare oral metoprolol with injection sclerotherapy in cirrhosis","volume":"26","author":"Westaby","year":"1985","journal-title":"Gut"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/gut.25.2.121","article-title":"Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension","volume":"25","author":"Westaby","year":"1984","journal-title":"Gut"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/liv.12360","article-title":"Beta-blockers in portal hypertension: New developments and controversies","volume":"34","author":"Tripathi","year":"2014","journal-title":"Liver Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/gutjnl-2012-304182","article-title":"Carvedilol: The \u03b2-blocker of choice for portal hypertension?","volume":"62","author":"Bosch","year":"2013","journal-title":"Gut"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2016.327","article-title":"A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients with Liver Cirrhosis","volume":"111","author":"Kim","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Vienna Hepatic Hemodynamic Lab. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/hep.28502","article-title":"Beta-blockers in 2016: Still the safest and most useful drugs for portal hypertension?","volume":"63","author":"Malizia","year":"2016","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/gutjnl-2011-301348","article-title":"The window hypothesis: Haemodynamic and non-haemodynamic effects of \u03b2-blockers improve survival of patients with cirrhosis during a window in the disease","volume":"61","author":"Krag","year":"2012","journal-title":"Gut"},{"key":"ref_62","first-page":"611","article-title":"Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension","volume":"20","author":"Albillos","year":"1994","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0016-5085(95)90586-3","article-title":"Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function","volume":"109","author":"Albillos","year":"1995","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/0016-5085(87)90921-8","article-title":"Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Pharmacokinetic-hemodynamic interactions","volume":"93","author":"Blei","year":"1987","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/0016-5085(89)91630-2","article-title":"Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis: Effects on splanchnic and systemic hemodynamics and liver function","volume":"96","author":"Navasa","year":"1989","journal-title":"Gastroenterology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1572-0241.2004.04051.x","article-title":"Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis","volume":"99","author":"Tripathi","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin\u2013angiotensin\u2013aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/1751-2980.12025","article-title":"Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease","volume":"14","author":"Agasti","year":"2013","journal-title":"J. Dig. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"46","author":"Abraldes","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2010.03.021","article-title":"Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension","volume":"53","author":"Bosch","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2174\/157016112803520918","article-title":"Statins and portal hypertension: A new pharmacological challenge","volume":"10","author":"Rojas","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial","volume":"47","author":"Soldan","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"BLEPS Study Group. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients with Cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1478-3231.2004.00892.x","article-title":"Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients","volume":"24","author":"Colle","year":"2004","journal-title":"Liver Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.cgh.2010.01.017","article-title":"Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis","volume":"8","author":"Tandon","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/CS20090601","article-title":"Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: The role of NO bioavailability","volume":"119","author":"Lee","year":"2010","journal-title":"Clin. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S471","DOI":"10.1016\/S0168-8278(18)31189-9","article-title":"FRI-247\u2014Udenafil decreases portal pressure and improves erectile dysfunction in liver cirrhosis","volume":"68","author":"Uschner","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/liv.14586","article-title":"Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction","volume":"40","author":"Uschner","year":"2020","journal-title":"Liver Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/9963\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:51:47Z","timestamp":1760125907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/9963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":79,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24129963"],"URL":"https:\/\/doi.org\/10.3390\/ijms24129963","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}